Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No reason to fear very low LDL

12.10.2005


Patients on statin treatment need not worry about cholesterol dropping too low

(Very low LDL cholesterol levels appear to be safe for heart patients on statin therapies, according to a new study in the Oct. 18, 2005, issue of the Journal of the American College of Cardiology.

"There was no apparent safety concern for patients whose resultant LDL on intensive therapy was lower than current guidelines. There was a trend toward improved clinical outcomes in the lowest LDL groups," said Stephen D. Wiviott, M.D., from Brigham and Women’s Hospital in Boston, Massachusetts.



The researchers used data from a large trial comparing two cholesterol-lowering statin drugs in patients following acute coronary syndromes, such as unstable angina or heart attacks, the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) study. This new analysis involved 1,825 heart patients who had received high doses (80 milligrams per day) of atorvastatin. More than 90 percent of the patients had LDL (low-density lipoprotein, the so-called "bad" cholesterol) levels below the target level of 100 milligrams per deciliter of blood after four months of therapy. Some patients saw their LDL levels drop below 40 mg/dl.

Dr. Wiviott said that they reviewed this data from PROVE IT because some studies have suggested an association between very low levels of cholesterol and higher rates of death, strokes caused by bleeding, and other health issues. Rather than assessing the safety of statin treatment itself, this analysis looked at the effects of various levels of LDL by comparing the results for patients who were all taking the same high doses of atorvastatin.

"While the main results of the trial demonstrated that intensive statin therapy is superior to moderate statin therapy in patients following acute coronary syndromes, there has been concern among the medical community about treating patients with very high doses of potent statins. This stems largely from the epidemiologic literature which shows that patients with very low cholesterol, not on treatment, have higher mortality," Dr. Wiviott said.

There was no significant difference in safety outcomes among the groups of patients, including rates of death, bleeding strokes, or muscle, liver or retinal abnormalities. What’s more, the patients who achieved LDL levels of 60 mg/dl or lower had fewer major cardiac events, including death, heart attack, stroke, recurrent coronary artery blockages or treatment to reopen coronary arteries.

Dr. Wiviott said the results offer reassurance to patients and clinicians using high doses of statins following acute coronary syndromes. "In order to achieve the greatest benefit following acute coronary syndromes, patients should be treated early with intensive statin therapy. There is no need to reduce the dose in follow-up just because LDL is well below targeted levels," he said.

Dr. Wiviott noted that the PROVE IT trial was not originally designed to answer questions about the safety of very low LDL levels.

"This type of analysis should be considered ’hypothesis generating’ and needs to be confirmed in other studies," he said.

John J.P. Kastelein, M.D. from the Academic Medical Center at the University of Amsterdam, Netherlands, who was not connected with this study, but who is helping to lead two large long-term studies of intensive statin therapy, welcomed this first solid information about the safety of low LDL levels.

"What’s very important for me is that this trial is the first indication that very low LDL levels are actually safe. Of course, the time frame is modest, but it is the first indication that we can sustain low LDL levels without any cost in terms of extra side effects," Dr. Kastelein said.

Amy Murphy | EurekAlert!
Further information:
http://www.acc.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>